Anti-Suicide Drugs Market
Suicidal behaviour is defined as the preoccupation or act that is focussed on causing one’s own death voluntarily. To have suicidal intent is to have a suicide or deliberate self-killing as one’s purpose. Intent refers to the aim, purpose, or goal of the behaviour. The term indicates a conscious desire or wishes to leave or escape from life, and also suggests a resolve to act. This is contrasted with suicidal motivation, or the driving force behind ideation or intent, which need not be conscious.
Some of the factors which are boosting the growth of Anti-Suicide Drugs Market are growing population with depression, increasing different depression disorders such as clinical depressive syndrome, postpartum depression, psychotic depression and seasonal affective disorder etc., and growing suicidal incidences worldwide. As per statistics of WHO around 8,00,000 people are committing suicide every year globally especially among the age group of 15 – 29 years. However, a dearth of effective therapies, growing drug abuse and rise in usage of unapproved therapies are the few factors which are expected to restrain the growth of anti-suicide drugs market.
A sample of this report is available upon request @
Anti-Suicide Drugs Market is segmented on basis of drug class, route of administration, end user, and geographical regions.
Based on the drug class, the global anti-suicide drugs market is segmented
- Anti-depressants
- Anti-anxiety drugs
- Anti-psychotic drugs
- NMDA Antagonists
- Antibiotic analogues
Based on the route of administration, the global anti-suicide drugs market is segmented
- Oral
- Parenteral
Based on the route of administration, the global anti-suicide drugs market is segmented
- Hospitals
- Clinics
- Online pharmacies
- Retail pharmacies
To view TOC of this report is available upon request @
Development of effective anti-suicidal drugs can be a major breakthrough in reducing the death rate. Currently, non-profit organizations like Stop Suicide, Stop youth suicide and American foundation for suicide prevention are providing social and moral support to the people with suicidal thoughts and tendencies. Increased focus on R&D led to the launch of new range of drugs and a strong pipeline of drugs, which in turn propel the growth of the anti-suicide drugs market. For example, NeuroRX (Acquired by Allergan) completed the phase-II trial for cycled (combination of lurasidone and D-Cycloserine, conjugated with ketamine) to treat suicidal tendencies associated with bipolar disorder.
Need more information about this report @
Anti-Suicide Drugs Market is segmented into North America, Asia-Pacific, Europe, and the Middle East & Africa, Latin America. North America and Europe are expected to gain attractive market share due to growing incidences of suicidal cases, rise in healthcare expenditure and launch a wide range of anti-suicidal drugs. As per, 2014 estimations of American Foundation for Suicide Prevention, the suicide rate in U.S was around 12.93 /1,000 people. Emerging countries in Asia Pacific region are expected to show the fastest growth during the forecast period due to growing awareness about the mental health, increasing visits of people to psychiatrists and psychologists, increase in the number of associations which are working on spreading the awareness, and rising suicide incidences. According to the data estimation of WHO in 2012, India, Russia, Guyana, Republic of Korea, Sri Lanka, Japan, and Kazakhstan are the nations with high suicidal rates.
Key players in the anti-suicide drugs market include AstraZeneca plc (UK), Allergan plc, Eli Lilly and Company (UK), H. Lundbeck A/S (Denmark), GlaxoSmithKline plc (UK), Johnson & Johnson (U.S), Merck & Co., Inc. (U.S), Pfizer, Inc. (U.S) to name some few.
Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-anti-suicide-drugs-market/